Item 8.01 Other Events.
On January 13, 2023, 180 Life Sciences Corp. (the "Company") entered into a
contract with Kinexum in the ordinary course of business (the "MSA"). Pursuant
to the MSA, Kinexum will provide assistance to the Company in connection with
the Conditional Marketing Authorisation (CMA) and Marketing Approval Application
(MAA) which the Company expects to submit to the UK Medicines and Healthcare
products Regulatory Agency (MHRA) in connection with the Company's planned use
of adalimumab to treat progressive early-stage Dupuytren's disease. Including
the costs associated with the Kinexum contract, the Company anticipates that it
will spend approximately $900,000 to $1,000,000 in the next three quarters for
activities associated with the MHRA filing and other regulatory preparation.
On January 17, 2023, the Company filed a press release disclosing the entry into
the MSA. A copy of the press release is included herewith as Exhibit 99.1 and
the information in the press release is incorporated by reference into this Item
8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Exhibit Description
99.1 Press Release, dated January 17, 2023
104 Cover Page Interactive Data File (embedded within Inline XBRL document).
1
© Edgar Online, source Glimpses